Caris Life Sciences (CAI) Net Margin (2024 - 2026)

Caris Life Sciences' Net Margin history runs 3 years deep, the most recent figure standing at 0.24% for Q1 2026.

• On a quarterly basis, Net Margin rose 10483.0% year-over-year to 0.24% in Q1 2026; TTM through Mar 2026 was 45.35%, a 3668.0% increase from a year earlier, with the FY2025 full-year figure at 66.25%, up 2550.0% from the prior year.
• Net Margin slipped to 0.24% in Q1 2026 per CAI's latest filing, from 27.98% in the prior quarter.
• Across five years, Net Margin topped out at 27.98% in Q4 2025 and bottomed at 285.12% in Q2 2025.
• The 3-year median for Net Margin is 68.71% (2024), against an average of 72.44%.
• Across the five-year window, Net Margin slumped 19538 bps in 2025 and surged 10483 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 47.68% in 2024, then soared by 159 bps to 27.98% in 2025, then sank by 101 bps to 0.24% in 2026.
• Per Business Quant, the three latest CAI Net Margin figures stand at 0.24% (Q1 2026), 27.98% (Q4 2025), and 11.22% (Q3 2025).